In addition, binding of TAM-derived CXCL1 to SOX4 promoter enhances its promoter activity via the NF-κB pathway, and silencing CXCL1 in TAMs showed a significant reduction in breast cancer progression and metastasis [177]. Here, CXCL1 is linked to breast carcinoma.